Moderate evidence supports use of venous thromboembolism prophylaxis (VTE) in hip fracture patients.

Management of Hip Fractures in the Elderly
Endorsed by: OTA, AGS, AAPM&R, ASBMR, USBJI, The Hip Society, AACE, ORA
Moderate Evidence MODERATE EVIDENCE
Rationale
One high strength study (PE Prevention Trial Collaborative Group107), three moderate strength studies (Moskovits et al167; Xabregas et al168; Morris et al169), and eight low strength studies (Chatanaphutiet al 108; Sasaki et al109; Sasaki et al110; Checketts et al111; Jorgensen et al112; Lahnborg et al113; Kew et al114; Eskeland et al115) were identified comparing various pharmacological prophylaxis interventions to placebo. One moderate strength study (Stranks et al115) compared mechanical prophylaxis to a group that received no mechanical prophylaxis.  These studies show the risk of DVT/VTE/PE complications is significantly less with VTE prophylaxis than control. Most general complications were not significantly different between treatment groups, with the exception of Lahnborg et al113 which found hematoma complications were higher in pharmacological prophylaxis groups. There was no difference in hospital stay and there is some evidence that mortality is less with prophylaxis.
 
Given the significant established risk factors for VTE present in this patient population including age, presence of hip fracture, major surgery, delays to surgery,  and the potential serious consequences of failure to provide prophylaxis in the hip fracture population,  it is the recommendation of the workgroup that VTE prophylaxis be used
 
Risks and Harms of Implementing this Recommendation
Patients with hip fracture are at high risk for deep venous thrombosis and pulmonary embolism. The consequences of symptomatic VTE are significant and include both increased morbidity and mortality. The harms associated with this recommendation include those associated with VTE prophylaxis, bleeding and thrombotic complications.
 
Future Research
The issue of VTE prophylaxis in patients who have sustained a hip fracture is complex. There are many unanswered questions that have the potential to have a significant impact on clinical outcomes for this patient population. A multi-armed randomized controlled study would be optimal. Such a study would potentially need to evaluate the comparative effectiveness of a multitude of chemical agents, at different dosages, with multiple time points (such as pre and post-op), and include assorted durations of therapy, while utilizing contemporary diagnostic methodologies. Barriers to such a study include the low incidence of the complication implicating a requirement for a substantially large sample size. Furthermore, such a study carries ethical concerns given the potential risks associated with under-treatment. Potentially, well organized patient outcome registries may ultimately help improve our knowledge in this area.

 
  1. (107) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355(9212):1295-1302.
  2. (108) Chotanaphuti T, Jareonarpornwatana A, Laoruengthana A. The mortality rate after thromboembolism prophylaxis in the hip fracture surgery. J Med Assoc Thai 2009;92 Suppl 6):S115-S119.
  3. (109) Sasaki S, Miyakoshi N, Matsuura H, Saitoh H, Kudoh D, Shimada Y. Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery. J Orthop Sci 2009;14(5):491-496.
  4. (110) Sasaki S, Miyakoshi N, Matsuura H et al. Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery. J Orthop Sci 2011;16(1):64-70.
  5. (111) Checketts RG, Bradley JG. Low-dose heparin in femoral neck fractures. Injury 1974;6(1):42-44.
  6. (112) Jorgensen PS, Knudsen JB, Broeng L et al. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study. Clin Orthop Relat Res 1992;(278):95-100.
  7. (113) Hinman RS, Crossley KM. Patellofemoral joint osteoarthritis: an important subgroup of knee osteoarthritis. Rheumatology (Oxford) 2007;46(7):1057-1062.
  8. (114) Kew J, Lee YL, Davey IC, Ho SY, Fung KC, Metreweli C. Deep vein thrombosis in elderly Hong Kong Chinese with hip fractures detected with compression ultrasound and Doppler imaging: incidence and effect of low molecular weight heparin. Arch Orthop Trauma Surg 1999;119(3-4):156-158.
  9. (115) Eskeland G, Solheim K, Skjorten F. Anticoagulant prophylaxis, thromboembolism and mortality in elderly patients with hip fractures. Acta Chir Scand 1966;131):16-29.
  10. (167) Moskovitz,P.A., Ellenberg,S.S., Feffer,H.L., Kenmore,P.I., Neviaser,R.J., Rubin,B.E., Varma,V.M. Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg Am 1978/12; 8: 1065-1070
  11. (168) Xabregas,A., Gray,L., Ham,J.M. Heparin prophylaxis of deep vein thrombosis in patients with a fractured neck of the femur. Med J Aust. 1978/6/3; 11: 620-622
  12. (169) Morris,G.K., Mitchell,J.R. Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. 1976/10/23; 7991: 869-872